Lara Magro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lara Magro has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Ugo Moretti
A Department of Diagnostics and Public Health, Section of Pharmacology , University of Verona , Verona , Italy
6 shared publicationsAnita Conforti
Pharmacology Unit, Department of Public Health and Community Medicine, University of Verona, Verona, Italy
4 shared publications- Domenico Motola
Unit of Pharmacology, Department of Medical and Surgical Sciences Alma Mater Studiorum University of Bologna Bologna Italy
4 shared publications - Roberto Leone
Veneto Regional Pharmacovigilance Centre, University of Verona, Piazzale Ludovico Antonio Scuro n.10, 37134, Verona, Italy.
3 shared publications - Francesco Salvo
INSERM, BPH, Team AHeaD, U1219 Université de Bordeaux Bordeaux France
2 shared publications I. Meneghelli
Clinical Pharmacology Unit, University of Verona, Verona, Italy
2 shared publications
Latest Publications
- Open Access
- 1 August 2018
- Published by Elsevier in The Lancet
- Vol. 392 (10145) , 383-384
Reporting of immune checkpoint inhibitor-associated myocarditis
- 1 August 2018
- Published by Elsevier in The Lancet
- Vol. 392 (10145) , 383-384
Open AccessReporting of immune checkpoint inhibitor-associated myocarditis
- 22 November 2016
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 15 (sup2) , 69-75
Italian monitoring registries: a tool for a safer use of innovative drugs? Data from the national pharmacovigilance system
Objectives: Our aim was to investigate the ADR reports of drugs with a monitoring registry (MR drugs), in particular those related to abuse/misuse, medication error, overdose, which might indicate an unsafe use. We compared these reports with those of similar drugs without a registry (non-MR drugs), thus verifying whether the registries could be useful tools for a safer use of innovative drugs. Methods: All ADR reports included in the Italian Pharmacovigilance Network database from January 1st 2013 to December 31st 2015 (vaccines and literature cases excluded) were analysed. We compared the ADR reports of MR and non-MR drugs with the same ATC class at III level. Results: The percentage of ADR reports with a completed ‘Section 7’ was significantly lower for MR compared to non-MR drugs (2.0 versus 6.2, p < 0.001). The difference concerned in particular the ADR reports related to abuse/misuse, medication errors and overdose. These reports, more strictly related to inappropriate use, were less frequent for MR drugs in all the considered ATC classes. Conclusions: Our study suggests that monitoring registries could be a useful tool for the reduction of frequency of ADRs related to inappropriate use, besides the control of pharmaceutical budget.
- 22 November 2016
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 15 (sup2) , 69-75
Italian monitoring registries: a tool for a safer use of innovative drugs? Data from the national pharmacovigilance system
Objectives: Our aim was to investigate the ADR reports of drugs with a monitoring registry (MR drugs), in particular those related to abuse/misuse, medication error, overdose, which might indicate an unsafe use. We compared these reports with those of similar drugs without a registry (non-MR drugs), thus verifying whether the registries could be useful tools for a safer use of innovative drugs. Methods: All ADR reports included in the Italian Pharmacovigilance Network database from January 1st 2013 to December 31st 2015 (vaccines and literature cases excluded) were analysed. We compared the ADR reports of MR and non-MR drugs with the same ATC class at III level. Results: The percentage of ADR reports with a completed ‘Section 7’ was significantly lower for MR compared to non-MR drugs (2.0 versus 6.2, p < 0.001). The difference concerned in particular the ADR reports related to abuse/misuse, medication errors and overdose. These reports, more strictly related to inappropriate use, were less frequent for MR drugs in all the considered ATC classes. Conclusions: Our study suggests that monitoring registries could be a useful tool for the reduction of frequency of ADRs related to inappropriate use, besides the control of pharmaceutical budget.
- 29 August 2014
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 13 (sup1) , 21-29
Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy
Adverse drug reaction (ADR) reporting by patients has a fundamental role in pharmacovigilance. The main objectives of the present study were to assess the impact of a pharmacist-based intervention in promoting direct patient reporting, to evaluate patient ability to identify and report ADRs and to determine their pattern. The study involved 96 pharmacists in the Campania region of Italy, who interviewed their customers and asked them whether they had experienced an ADR. Patients who had experienced an ADR were invited to complete an ADR reporting form. The quality of completed ADR reporting forms was evaluated before their entry into the Italian Spontaneous Reporting System (Rete Nazionale di Farmacovigilanza [RNF]) and, once entered, their pattern was determined. A total of 18,677 patients were interviewed, and 10.88% had experienced an ADR. After quality control, 54.32% of all reporting forms were entered into the RNF so that patient contribution to spontaneous reporting, null over the years, reached ∼7%. Patients reported mainly non-serious (91.28%) and expected (94.62%) ADRs, and NSAIDs or antibiotics were the most frequently reported drugs. The study shows that pharmacists can have an important role in promoting patient reporting and adds new information on how a patient reporting form should be structured.
- 29 August 2014
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 13 (sup1) , 21-29
Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy
Adverse drug reaction (ADR) reporting by patients has a fundamental role in pharmacovigilance. The main objectives of the present study were to assess the impact of a pharmacist-based intervention in promoting direct patient reporting, to evaluate patient ability to identify and report ADRs and to determine their pattern. The study involved 96 pharmacists in the Campania region of Italy, who interviewed their customers and asked them whether they had experienced an ADR. Patients who had experienced an ADR were invited to complete an ADR reporting form. The quality of completed ADR reporting forms was evaluated before their entry into the Italian Spontaneous Reporting System (Rete Nazionale di Farmacovigilanza [RNF]) and, once entered, their pattern was determined. A total of 18,677 patients were interviewed, and 10.88% had experienced an ADR. After quality control, 54.32% of all reporting forms were entered into the RNF so that patient contribution to spontaneous reporting, null over the years, reached ∼7%. Patients reported mainly non-serious (91.28%) and expected (94.62%) ADRs, and NSAIDs or antibiotics were the most frequently reported drugs. The study shows that pharmacists can have an important role in promoting patient reporting and adds new information on how a patient reporting form should be structured.
- 9 March 2013
- Published by Springer Nature in Drug Safety
- Vol. 36 (4) , 267-276
Effect of Pharmacist Involvement on Patient Reporting of Adverse Drug Reactions: First Italian Study
Background Adding patients to the range of potential reporters of adverse drug reactions (ADRs) may increase spontaneous reporting and contribute to the detection of signals, one of the primary aims of spontaneous reporting systems. Community pharmacies could have an important role in this context as a service for promoting patient reporting of ADRs. Objectives The main objectives of the present study were to assess the potential impact of an intervention to promote patient reporting in community pharmacies in the Veneto region of Italy, and to compare the characteristics of patients’ and general practitioners’ (GPs) reports of ADRs. Methods The study was conducted in the Veneto region of Italy and involved 211 pharmacists working in 118 community pharmacies. Each pharmacist was asked to select, during the study period, about 250 customers who had received at least one drug, and then to present the spontaneous reporting form to those who had experienced a suspected ADR. Patients were asked to complete the ADR report form and either give it back to the pharmacist, or send it by fax or mail, or else to fill in the form online. Results In a 4-month period, 52,495 customers were interviewed by the pharmacists and 4,949 of them (9.4 %) referred a suspected ADR. The Pharmacovigilance Centre of the Veneto region received 2,311 citizen’s ADR reporting forms related to the study (from 46.7 % of all patients interviewed who had experienced suspected ADRs). After quality control 1,794 of these reports were entered into the Italian Pharmacovigilance Database and were compared with the reports (226) sent by GPs in the Veneto region in the same period. Patients reported a higher percentage of known and non-serious reactions than did GPs. Drugs widely used in the community setting, and over-the-counter products, were the drugs most frequently reported by patients. In contrast, few reports involving reactions to antineoplastic agents or contrast media—drugs mostly used in a hospital setting—were sent by patients. Conclusions Our study shows that patient reporting has the potential to add value to the pharmacovigilance system. The overall quality of the information provided in patients’ reports was good. The differences between reports by patients and by GPs indicate different points of view that can enrich spontaneous reporting.
- 9 March 2013
- Published by Springer Nature in Drug Safety
- Vol. 36 (4) , 267-276
Effect of Pharmacist Involvement on Patient Reporting of Adverse Drug Reactions: First Italian Study
Background Adding patients to the range of potential reporters of adverse drug reactions (ADRs) may increase spontaneous reporting and contribute to the detection of signals, one of the primary aims of spontaneous reporting systems. Community pharmacies could have an important role in this context as a service for promoting patient reporting of ADRs. Objectives The main objectives of the present study were to assess the potential impact of an intervention to promote patient reporting in community pharmacies in the Veneto region of Italy, and to compare the characteristics of patients’ and general practitioners’ (GPs) reports of ADRs. Methods The study was conducted in the Veneto region of Italy and involved 211 pharmacists working in 118 community pharmacies. Each pharmacist was asked to select, during the study period, about 250 customers who had received at least one drug, and then to present the spontaneous reporting form to those who had experienced a suspected ADR. Patients were asked to complete the ADR report form and either give it back to the pharmacist, or send it by fax or mail, or else to fill in the form online. Results In a 4-month period, 52,495 customers were interviewed by the pharmacists and 4,949 of them (9.4 %) referred a suspected ADR. The Pharmacovigilance Centre of the Veneto region received 2,311 citizen’s ADR reporting forms related to the study (from 46.7 % of all patients interviewed who had experienced suspected ADRs). After quality control 1,794 of these reports were entered into the Italian Pharmacovigilance Database and were compared with the reports (226) sent by GPs in the Veneto region in the same period. Patients reported a higher percentage of known and non-serious reactions than did GPs. Drugs widely used in the community setting, and over-the-counter products, were the drugs most frequently reported by patients. In contrast, few reports involving reactions to antineoplastic agents or contrast media—drugs mostly used in a hospital setting—were sent by patients. Conclusions Our study shows that patient reporting has the potential to add value to the pharmacovigilance system. The overall quality of the information provided in patients’ reports was good. The differences between reports by patients and by GPs indicate different points of view that can enrich spontaneous reporting.
- Open Access
- 15 June 2012
- Published by Seed SRL in Pratica Medica & Aspetti Legali
- Vol. 6 (2) , 43-50
Rilevanza clinica e aspetti medico-legali delle interazioni tra farmaci
Rilevanza clinica e aspetti medico-legali delle interazioni tra farmaci
- 15 June 2012
- Published by Seed SRL in Pratica Medica & Aspetti Legali
- Vol. 6 (2) , 43-50
Open AccessRilevanza clinica e aspetti medico-legali delle interazioni tra farmaci
Rilevanza clinica e aspetti medico-legali delle interazioni tra farmaci
- Top Cited Papers
- 25 October 2011
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 11 (1) , 83-94
Epidemiology and characteristics of adverse drug reactions caused by drug–drug interactions
Introduction: Drug–drug interactions (DDIs) arise in numerous different ways, involving pharmacokinetic or pharmacodynamic mechanisms. Adverse drug reactions are a possible consequence of DDIs and health operators are often unaware of the clinical risks of certain drug combinations. Many papers on drug interactions have been published in recent years, but most of them focused on potential DDIs while few studies have been conducted on actual interactions. Areas covered: This paper reviews the epidemiology of actual DDIs in outpatients as well as in hospital settings and in spontaneous reporting databases. The incidence of actual DDIs is consistently lower than that of potential DDIs. However, the absolute number of patients involved is high, representing a significant proportion of adverse drug reactions. The importance of risk factors such as age, polypharmacy and genetic polymorphisms is also evaluated. The relevance and efficacy of tools for recognizing and preventing DDIs are discussed. Expert opinion:...
- 25 October 2011
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 11 (1) , 83-94
Top Cited PapersEpidemiology and characteristics of adverse drug reactions caused by drug–drug interactions
Introduction: Drug–drug interactions (DDIs) arise in numerous different ways, involving pharmacokinetic or pharmacodynamic mechanisms. Adverse drug reactions are a possible consequence of DDIs and health operators are often unaware of the clinical risks of certain drug combinations. Many papers on drug interactions have been published in recent years, but most of them focused on potential DDIs while few studies have been conducted on actual interactions. Areas covered: This paper reviews the epidemiology of actual DDIs in outpatients as well as in hospital settings and in spontaneous reporting databases. The incidence of actual DDIs is consistently lower than that of potential DDIs. However, the absolute number of patients involved is high, representing a significant proportion of adverse drug reactions. The importance of risk factors such as age, polypharmacy and genetic polymorphisms is also evaluated. The relevance and efficacy of tools for recognizing and preventing DDIs are discussed. Expert opinion:...
- 1 August 2010
- Published by Springer Nature in Drug Safety
- Vol. 33 (8) , 667-675
Identifying Adverse Drug Reactions Associated with Drug-Drug Interactions
Background: Drug-drug interactions (DDIs) are an important cause of adverse drug reactions (ADRs). Many studies have recently considered this issue, but most of them focus only on potential interactions and are often related to the hospital setting. A spontaneous reporting database could be a valuable resource for detection of ADRs associated with DDIs; however, data in the literature are limited. Objective: To detect those patients treated with potentially interacting drugs and the cases where reported adverse reactions are a possible consequence of DDIs, using an Italian spontaneous reporting database. Methods: The data were obtained from a database containing all reports of suspected ADRs from five Italian regions (January 1990 to December 2007) that are the main contributors to the Italian spontaneous reporting system. All reports containing at least two drugs, reported as being suspected of causing the ADR or as concomitant medication, were selected and a list of drug pairs was drawn up. We performed a search to verify which drug pairs are considered a potential DDI, using the Internet version of the DRUGDEX® system. For each report containing a potential DDI, we verified whether the description of the adverse reaction corresponded to the interaction effect. Results: The database contained 45 315 reports, of which 17 700 (39.1%) had at least two reported drugs. We identified 5345 (30.2%) reports with potential DDIs, and in 1159 (21.7%) of these reports a related ADR was reported. The percentage of reports with potential DDIs increased in relation to the number of concomitantly administered drugs, ranging from 9.8% for two drugs to 88.3% for eight or more drugs. The percentages of serious or fatal reports of ADRs associated with a DDI were significantly higher than other reports analysed. The mean age, percentage of male patients and the mean number of drugs were also significantly higher in reports with DDIs than in other reports. In 235 of 1159 reports (20.3%), both interacting drugs were recognized as suspect by the reporter. This percentage varies in relation to the drugs involved, ranging from 2% to about 65%. The most frequently reported interaction was digoxin and diuretics, but no fatal ADRs were reported with this combination. The combination of anticoagulant and antiplatelet agents was responsible for the greatest number of serious reactions and deaths. Conclusions: This study validates that spontaneous reporting, despite its limitations, can be an important resource for detecting ADRs associated with the concomitant use of interacting drugs. Moreover, our data confirm that DDIs could be a real problem in clinical practice, showing that more than one in five patients exposed to a potential DDI experienced a related ADR.
- 1 August 2010
- Published by Springer Nature in Drug Safety
- Vol. 33 (8) , 667-675
Identifying Adverse Drug Reactions Associated with Drug-Drug Interactions
Background: Drug-drug interactions (DDIs) are an important cause of adverse drug reactions (ADRs). Many studies have recently considered this issue, but most of them focus only on potential interactions and are often related to the hospital setting. A spontaneous reporting database could be a valuable resource for detection of ADRs associated with DDIs; however, data in the literature are limited. Objective: To detect those patients treated with potentially interacting drugs and the cases where reported adverse reactions are a possible consequence of DDIs, using an Italian spontaneous reporting database. Methods: The data were obtained from a database containing all reports of suspected ADRs from five Italian regions (January 1990 to December 2007) that are the main contributors to the Italian spontaneous reporting system. All reports containing at least two drugs, reported as being suspected of causing the ADR or as concomitant medication, were selected and a list of drug pairs was drawn up. We performed a search to verify which drug pairs are considered a potential DDI, using the Internet version of the DRUGDEX® system. For each report containing a potential DDI, we verified whether the description of the adverse reaction corresponded to the interaction effect. Results: The database contained 45 315 reports, of which 17 700 (39.1%) had at least two reported drugs. We identified 5345 (30.2%) reports with potential DDIs, and in 1159 (21.7%) of these reports a related ADR was reported. The percentage of reports with potential DDIs increased in relation to the number of concomitantly administered drugs, ranging from 9.8% for two drugs to 88.3% for eight or more drugs. The percentages of serious or fatal reports of ADRs associated with a DDI were significantly higher than other reports analysed. The mean age, percentage of male patients and the mean number of drugs were also significantly higher in reports with DDIs than in other reports. In 235 of 1159 reports (20.3%), both interacting drugs were recognized as suspect by the reporter. This percentage varies in relation to the drugs involved, ranging from 2% to about 65%. The most frequently reported interaction was digoxin and diuretics, but no fatal ADRs were reported with this combination. The combination of anticoagulant and antiplatelet agents was responsible for the greatest number of serious reactions and deaths. Conclusions: This study validates that spontaneous reporting, despite its limitations, can be an important resource for detecting ADRs associated with the concomitant use of interacting drugs. Moreover, our data confirm that DDIs could be a real problem in clinical practice, showing that more than one in five patients exposed to a potential DDI experienced a related ADR.
- 17 October 2009
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 66 (2) , 199-206
Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents
The aim of the present study was to collect and compare cases of drug-induced PML in order to contribute to the debate about the role of the underlying diseases and/or drug immunosuppression in PML occurrence.
- 17 October 2009
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 66 (2) , 199-206
Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents
The aim of the present study was to collect and compare cases of drug-induced PML in order to contribute to the debate about the role of the underlying diseases and/or drug immunosuppression in PML occurrence.
- 1 January 2008
- Published by Springer Nature in Drug Safety
- Vol. 31 (10) , 885-960
Evaluation and Comparison of Two Methods of Causality Assessment in an Italian Spontaneous Reporting Database
- 1 January 2008
- Published by Springer Nature in Drug Safety
- Vol. 31 (10) , 885-960
Evaluation and Comparison of Two Methods of Causality Assessment in an Italian Spontaneous Reporting Database